Amalia Gastaldelli

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

Michael Pavlides, Yasaman Vali, Ferenc Emil Mózes, Kristy Wonders et autres

There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), …

gb, nl, de, se, es, us, dk, fr, ch, fi, gr, it (code pays fourni par la source)

OS-018 Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagonlike peptide-1 receptor dual agonist, in a phase 2 trial

Raphael Hesse, Panagiotis Papavasileiou, Ahmad Alhussein, Renee Marshall et autres

THU-213 Global economic burden of metabolic dysfunction–associated steatohepatitis (MASH) in individuals with type 2 diabetes (T2D) across nine countries

Zobair M. Younossi, James M. Paik, Frank Tacke, Patrizia Burra et autres

FRI-150-YI Adipose tissue insulin resistance is a marker and amajor driver of severe metabolic dysfunction associated steatohepatitis

Nateneal Beyene, Joel Haas, Silvia Sabatini, Wilhelmus J Kwanten et autres

SAT-050 Type 2 diabetes (T2D) is the major driver of advanced metabolic dysfunction–associated steatohepatitis (MASH) and associated liver-related mortality in Europe

Zobair M. Younossi, James M. Paik, Frank Tacke, Patrizia Burra et autres

WED-153 Accuracy of non-invasive tests for ruling out or in advanced fibrosis in MASLD patients across clinical settings: a systematic review and meta-analysis

Douglas Maya-Miles, Evangelia Mentsiou-Nikolaou, Isabel Fernández-Lizaranzu, Fariba Ahmadizar et autres

WED-084 GRIPonMASH preliminary results: comparison of FIB-4 and MAF-5 as first-line tests to rule out advanced fibrosis in primary care

Vivian de Jong, Caterina Buranelli, Kirsi van Eekhout, Leonard (Niels) Broekman et autres

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

Zobair M. Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M. Al-Naamani et autres

us, hk, om, de, gb, es, Égypte, cl, fr, Afrique du Sud, it, br, ar, in, my, cn, nl, tw, ca, jp, ph, tr, gr, au, sa, il (code pays fourni par la source)

Rethinking Liver Transaminases to Predict Diabetes Risk in Children With MASLD

Melania Manco, Amalia Gastaldelli

it (code pays fourni par la source)